The U.S. Centers for Disease Control and Prevention (CDC) - Public Health Grand Rounds – recently hosted a webinar on “Overcoming Barriers to Medication Adherence for Chronic Diseases.”The event brought together a panel of leaders in pharmacy, nursing, medicine, academia, and public health to discuss the burden of medication nonadherence and barriers for adherence among patients with chronic diseases—including HIV/AIDS.
Medication nonadherence manifests in two distinct behaviors: intentional, such as choosing to forgo filling a prescription because of cost, or unintentional, where patients simply forget to take their medication or are unable to manage multiple medications or complex treatment regimens. The panelists highlighted how intervention strategies aimed at medication adherence can positively affect patient health outcomes. (more…)
Value-based pharmaceutical pricing, aimed at achieving better value for pharmaceutical spending and lowering drug prices, while maintaining innovation, is a concept that is gaining traction. In the U.S., prescription drug prices are set by pharmaceutical companies to maximize profits, not based on how well a drug works. In contrast, according to its proponents, value-based drug pricing would mean real health outcomes (not just profits) determine the cost of a drug.
President-Elect Trump’s push for healthcare reform that focuses on free market, consumer-driven initiatives will enhance the political viability of value-based drug pricing. It has more support by the pharmaceutical industry than other popular policies to bring down drug prices, as it’s viewed as more in line with free market principles than other policy proposals, such as allowing Medicare to negotiate drug prices.